Nivolumab is a fully-humanized anti-PD-1 monoclonal antibody that selectively blocks the interaction of PD-1 with its receptors BRAF and programmed death-ligand 2 (PD-L2) and restores T-cell response directed at tumor cells, inducing an anti-tumor effect [7]. Here, BRAF is linked to neoplasm.